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The last two decades have seen great improvements in
the treatment of hepatic colorectal metastases. The 1990s
saw the maturation of data ﬁrmly establishing surgical
resection as an effective and potentially curative therapy
for this once uniformly fatal disease.
1,2 In the last decade,
introduction of systemic treatments such as oxaliplatin,
irinotecan, bevacizumab, and cetuximab have added to
favorable outcomes by increasing the number of patients
eligible for resection, as well as by decreasing recurrence.
3
Fifteen to 20% of patients with previously unresectable
disease now have disease that is downstaged routinely by
effective chemotherapy to a resectable state.
3 On the basis
of these data, oncologists in the United States have
extended the preoperative use of chemotherapy to include
not only those patients with unresectable disease (down-
staging strategy), but also those patients with initially
resectable disease (neoadjuvant strategy). The article in
this issue by Reddy et al. is part of a growing body of data
indicating that such liberal use of prehepatic resection
chemotherapy may not be justiﬁed.
4
Many theoretical justiﬁcations have been provided for
the routine use of neoadjuvant chemotherapy (Table 1).
These include the following: (1) Use of preoperative che-
motherapy allows in vivo chemosensitivity determination
by observing the response of tumors not yet resected (2)
The additional waiting period allows distant disease to be
established as unresectable for cure (3) The preoperative
chemotherapy may produce better outcomes by treating
undetectable disease early on (4) The period of chemo-
therapy treatment may allow patients after recent
colectomy ample time to recover before a hepatic
resection.
It turns out that only the last may be substantiated by the
data. Because 72% of patients respond to cetuximab and
FOLFOX chemotherapy and another 23% may have stable
disease, it is the unusual patient (5%) who experiences
disease progression while receiving ﬁrst-line therapy.
5 In a
recent study of perioperative chemotherapy, only 7%
experienced progression of disease.
6 Another article in the
current issue demonstrates the progression of disease in
only 10% of patients who receive neoadjuvant chemo-
therapy.
7 The waiting period did little to identify patients
with systemic disease because only 4 of 182 patients
experienced an increase in number or sites of tumors,
which would rule out resection.
6 Thus, it is only after
failure of ﬁrst-line therapy that the concept of in vivo
chemosensitivity testing makes sense. With improvements
in identifying molecular predictors of response, resection
early, on with thorough interrogation of the tissues, will
probably prove to be a better strategy for choosing among
chemotherapies. For example, one of the most important
recent discoveries in the ﬁeld was the ﬁnding that tumor
analysis for K-ras mutation status can be used as a reliable
predictor of response to cetuximab and oxaliplatin.
8
Moreover, there is increasing evidence that preoperative
chemotherapy may have substantial detrimental effects.
The syndrome of chemotherapy-associated steatohepatitis
is now well recognized.
9 This syndrome is characterized by
steatosis, splenomegaly, and thrombocytopenia—results of
liver damage and portal hypertension. The clinical impli-
cations of such tissue damage on complications and
postoperative recovery after liver resection are increasingly
being reported.
10 Given that, to date, no trial has clearly
proven a role for preoperative chemotherapy, such neoad-
juvant use of chemotherapy should not be regarded as the
standard of care.
What should surgeons do now? If the patient has syn-
chronous primary and metastatic disease that can be safely
removed in the same operation, a combined resection is
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11 If the primary colorectal cancer has been
removed, a delay in resection of synchronous secondaries
may be justiﬁed by the need to recover from the primary
resection. Such use of chemotherapy before subsequent
liver resection is particularly attractive for patients with
extensive regional nodal metastases or positive margins on
the primary tumor resection.
The data in Reddy et al. show that a complete course of
chemotherapy after liver resection is beneﬁcial.
4 What is
unknown is whether postoperative chemotherapy was
found to be useful because it was given in an uninterrupted
course. Thus, an interesting trial for patients who have had
the primary cancer removed but still had synchronous liver
metastases in place is one randomizing these patients to 6
continuous months of chemotherapy before liver resection,
versus treating them with 2 to 3 months of chemotherapy
followed by resection and then adjuvant therapy. For
patients with metachronous metastases, preoperative che-
motherapy is only currently justiﬁed if disease is borderline
or unresectable. All others should undergo resection fol-
lowed by adjuvant chemotherapy except in the setting of
trials.
What is the adjuvant therapy of choice? Accumulated
evidence supports the notion that adjuvant therapy after
liver resection is beneﬁcial. Both randomized trials and
retrospective data indicate that systemic 5-ﬂuorouracil/
leucovorin (5-FU/LV) improves outcome.
12,13 Extrapola-
tion of data from stage III colorectal cancer would indicate
that FOLFOX chemotherapy would also be a reasonable
regimen. Thus, if the patient has not previously received
chemotherapy, both 5-FU/LV and FOLFOX regimens are
justiﬁed. Trials comparing these two regimens in the
adjuvant setting are still needed. More controversy exists
for those with disease that has failed to respond to ﬁrst-line
adjuvant therapy. Molecular proﬁles of the tumors, in
particular K-ras mutations, will help guide the choice of
second-line therapies in the future. Patients whose disease
has failed to respond to FOLFOX or FOLFIRI are often
placed on irinotecan/cetuximab or Xeloda/bevacizumab
regimen, but this treatment is based on few data, and it
generates costs of up to $100,000 for a 6-month course.
Such patients should be entered onto available trials or
registries to accurately deﬁne the effects of such treat-
ments. Although these agents have greatly improved
outcomes in colorectal cancer, their precise role in offering
cost-effective clinical beneﬁts remains to be seen. Devel-
opment of other effective therapies and other assays
predicting response are priorities for research in this ﬁeld.
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TABLE 1 Rationale for use of preoperative chemotherapy in patients with liver metastases
Rationale Justiﬁcation Evidence against
As an attempt to downstage
patients for resection
To increase number of patients
eligible for resection
15–20% of disease is converted to
resectable;
3 long-term survival of patients
documented after resection
3
As neoadjuvant therapy for
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6 there is increasing evidence that resection
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volume disease outside the liver
To allow treatments of and
possible eradication of
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improve long-term outcome over postoperative
chemotherapy alone
To allow patients to recover from
colectomy/proctectomy before
liver resection
Many patients have weight loss and
debilitation post-surgery. In particular,
patients with complications from the
colectomy/proctectomy may fall into this
category
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